Precision Medicine

Personalis Announces Scientific Collaboration with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with Sarepta Therapeutics (Nasdaq: SRPT), a leader in precision genetic medicine for rare disease. As part of this research collaboration, Sarepta will be working with the Personalis team to characterize immune response to precision genetic therapeutics, utilizing Personalis’ advanced …

Read More »

Roche Acquires Stratos Genomics to Further Develop DNA Based Sequencing for Diagnostic Use

Basel, 22 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has acquired Stratos Genomics, an early-stage sequencing technology company to advance the development of Roche’s nanopore sequencer. The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX™). The Roche nanopore sequencer, …

Read More »

Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship

KENILWORTH, N.J. & PITTSBURGH–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and UPMC today announced that Infectious Disease Connect Inc., a UPMC-backed company offering telemedicine-enabled solutions to hospitals for treatment of infectious diseases, has combined with Merck’s ILÚM Health Solutions, a provider of technology and services to support infectious disease …

Read More »

Roche Enters Drug Discovery Collaboration with Vividion Focused on Novel E3 Ligases

SAN DIEGO, May 19, 2020 /PRNewswire/ — Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced that it has entered into an exclusive worldwide option and license agreement with Roche (SIX: RO, ROG;OTCQX: RHHBY) to leverage its proteomics screening …

Read More »

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus today announced a large-scale research collaboration designed to advance the field of human genetics and precision medicine through the sharing of 450,000 DNA samples and corresponding health records from de-identified, consented patient participants in …

Read More »

Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19

SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced the selection of a development candidate (DC) for VIR-2703 (also referred to as ALN-COV), an investigational RNAi therapeutic targeting the SARS-CoV-2 genome. The companies plan to soon meet with the U.S. Food …

Read More »

Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers

KENILWORTH, N.J. & SEATTLE–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the Institute for Systems Biology (ISB), today announced a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines. Merck has …

Read More »

Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Second Genome, a leader in microbiome science, today announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds in inflammation, …

Read More »

Proscia and UCSF Partner to Deliver Artificial Intelligence Applications That Improve the Accuracy and Speed of Cancer Diagnosis

PHILADELPHIA & SAN FRANCISCO–(BUSINESS WIRE)–Proscia, a leading provider of artificial intelligence (AI) enabled digital pathology solutions, and the University of California, San Francisco (UCSF) have partnered to introduce artificial intelligence into the practice of pathology. Beginning with prostate cancer, the second leading cause of cancer deaths among men in the …

Read More »

Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases

CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced biomarker data for EDP1815, its lead inflammation product candidate. Interim data from individuals in the ongoing Phase 1b clinical trial showed …

Read More »